Fiche publication


Date publication

janvier 2015

Journal

Experimental hematology & oncology

Auteurs

Membres identifiés du Cancéropôle Est :
Pr AUBIN François , Pr BORG Christophe , Pr DECONINCK Eric , Dr FERRAND Christophe , Pr GARNACHE-OTTOU Francine , Dr GODET Yann , Dr LAROSA Fabrice , Pr TOUSSIROT Eric


Tous les auteurs :
Gamonet C, Bole-Richard E, Delherme A, Aubin F, Toussirot E, Garnache-Ottou F, Godet Y, Ysebaert L, Tournilhac O, Caroline D, Larosa F, Deconinck E, Saas P, Borg C, Deschamps M, Ferrand C

Résumé

CD20 is a B cell lineage-specific marker expressed by normal and leukemic B cells and targeted by several antibody immunotherapies. We have previously shown that the protein from a CD20 mRNA splice variant (D393-CD20) is expressed at various levels in leukemic B cells or lymphoma B cells but not in resting, sorted B cells from the peripheral blood of healthy donors.

Mots clés

Alternative splicing, B malignancies, CD20, CLL, EBV transformation

Référence

Exp Hematol Oncol. 2015 ;5:7